Compare PDSB & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDSB | NEPH |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 40.1M |
| IPO Year | 2015 | 2004 |
| Metric | PDSB | NEPH |
|---|---|---|
| Price | $0.76 | $4.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.00 | $6.00 |
| AVG Volume (30 Days) | ★ 246.2K | 8.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.16 | ★ 1000.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $359.00 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.51 | $2.66 |
| 52 Week High | $1.55 | $6.42 |
| Indicator | PDSB | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.85 | 52.48 |
| Support Level | $0.63 | $3.19 |
| Resistance Level | $0.76 | $3.78 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 76.46 | 60.00 |
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.